Unknown

Dataset Information

Lenalidomide improves NKG2D-based CAR-T cell activity against colorectal cancer cells invitro.


ABSTRACT:

Introduction

Although CAR-based immunotherapy is viewed as a promising treatment for tumors, particularly hematological malignancies, solid tumors can pose challenges. It has been suggested that the immunomodulatory medication Lenalidomide (LEN) may increase the effectiveness of CAR T cells in the treatment of solid tumors. The purpose of our study was to investigate the effect of NKG2D-based CAR T cell therapy on colorectal cancer cell lines, and then we assessed combinatorial therapy using NKG2D CAR T cells and lenalidomide in vitro.

Methods and results

To prepare NKG2D CAR T cells, a second-generation NKG2D-CAR construct was designed and transfected into the T cells using a lentiviral system. The NKG2D CAR T cells showed significantly higher cytotoxic activity against col

SUBMITTER: Zarei M 

PROVIDER: S-EPMC10543764 | biostudies-literature | 2023 Oct

REPOSITORIES: biostudies-literature